Insmed Q1 FY26 net loss narrows to $163.6 million; revenue rises to $306 million

Insmed Incorporated

Insmed Incorporated

INSM

0.00
  • Insmed posted a net loss of USD 163.6 million, or USD 0.76 per share, as revenue climbed more than tripled to USD 306 million.
  • R&D expense rose to USD 209.5 million, while SG&A costs increased to USD 247.3 million.
  • BRINSUPRI revenue reached USD 207.9 million, while ARIKAYCE revenue increased 6% year over year to USD 98.1 million.
  • Phase 3b ENCORE study of ARIKAYCE in MAC lung disease met primary and all multiplicity-controlled secondary culture conversion endpoints; plans call for an sNDA submission in the second half of 2026.
  • Guidance maintained for 2026 BRINSUPRI revenue of at least USD 1 billion, while ARIKAYCE expected at USD 450 million to USD 470 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY52914) on May 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.